New Alzheimer’s Drug Could Receive National Coverage Policy, Now Under Medicare Review
On July 12, 2021, the Centers for Medicare & Medicaid Services (CMS) announced the opening of a National Coverage Determination (NCD) analysis. The government agency says the process will allow an advanced and careful review to determine whether Medicare will establish a national coverage policy for monoclonal antibodies targeting Alzheimer’s disease. Monoclonal antibodies may prevent beta-amyloid from clumping into plaques or remove beta-amyloid plaques that have formed and help the body clear the beta-amyloid from the brain, found in patients diagnosed with Alzheimer’s.
- When someone is diagnosed with Alzheimer’s (or dementia), they will require more care, patience, and support as they grow older.